An Introduction to Pulmonary Hypertension
With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape
Pulmonary Hypertension Content
Medical therapy for CTEPH: What is the standard of care in 2020?
Watch a panel of internationally renowned chronic thromboembolic pulmonary hypertension (CTEPH) experts discuss medical therapy for CTEPH, and consider the current standard of care using case-based studies to provide practical guidance on the optimal clinical management of patients with CTEPH.
- Discuss best practice for the multidisciplinary assessment of CTEPH
- Apply medical therapy for inoperable patients with CTEPH
- Perform medical therapy for patients with post-operative persistent/recurrent symptomatic disease
Medical Therapy for CTEPH: From biology to new treatment options
Watch leading experts involved in the care of patients with CTEPH discuss the latest issues and controversies in the medical management of CTEPH and related comorbidities
- Describe the biological and pathophysiological mechanisms of CTEPH
- Summarize the evolving data supporting the use of oral therapies
- Explain how new developments in medical therapy for the treatment of CTEPH will change daily practice
Luis Jara Palomares, ERS 2019 – Environmental Factors in Pulmonary Embolism and PAH
Luis Jara-Palomares, from Seville, Spain, joins us at ERS 2019 in Madrid, to discuss the main findings from his study into the significance of environmental factors in pulmonary embolism and pulmonary arterial hypertension. Questions 1. What are the major causes of pulmonary embolism and pulmonary arterial hypertension? (0:06) 2. What is known about the impact […]
Sandeep Sahay, ATS 2019 – New World Symposium Proceedings on Pulmonary Hypertension
Sandeep Sahay (Houston Methodist Lung Center, Houston Methodist Hospital, Houston, TX, USA) speaks from the 2019 ATS conference in Dallas, TX, USA about portopulmonary hypertension, how it differs from other types of hypertension and changes to the diagnostic criteria. He also addresses the changes this will have on patients and addressing unmet needs in hypertension. […]
James R Klinger, CHEST 2018 – Management of pulmonary arterial hypertension
James R Klinger (Rhode Island Hospital, and Warren Alpert Medical School, Brown University, Providence, RI, US) chats to us on the topic of his session entitled: Current Quandaries in Pulmonary Arterial Hypertension (PAH) Management. Questions 1. What are the major challenges in the management of pulmonary arterial hypertension (PAH)? (0:10) 2. What have been the […]
Namita Sood, CHEST 2018 – Pulmonary arterial hypertension: diagnosis and current therapies
Namita Sood (University of Texas Health Science Center, Houston, TX, US) discusses challenges and advances in pulmonary arterial hypertension (PAH). Questions 1. What is the definition of pulmonary arterial hypertension (PAH)? (0:10) 2. What are the major challenges in the diagnosis of PAH? (0:43) 3. How is PAH classified and what are the most important […]
Pulmonary Arterial Hypertension Management – A New Approach For a Rare Disease
European Respiratory & Pulmonary Diseases, 2016;2(2):50–1 DOI: //doi.org/10.17925/ERPD.2016.02.02.50
Pulmonary arterial hypertension (PAH) is a rare, deadly and incurable condition.1 With a five-year survival rate below 60%, the outcome of this disease is not any better than that of many cancers.1,2 However, numerous treatment options are currently available: more than 20 randomised controlled trials (RCTs) have been conducted over the past 10 years, allowing […]
Poster session highlights: Portopulmonary hypertension
Hilary DuBrock, Pulmonary Fellow at Massachusetts General Hospital, highlights two posters presented at the 2015 ATS annual conference. The first of these studies was a comparison of endothelin gradients across the pulmonary circulation of patients with PPHTN versus patients with cirrhosis. The second study looked at post transplant outcomes to better understand the role of […]
Right heart parameters in patients with left heart disease-associated pulmonary hypertension
Dr. Paul Forfia discusses his poster evaluating right heart parameters in patients with left heart disease-associated pulmonary hypertension. His research found the combination of TAPSE (a measure of right heart function) and Doppler notching (an index of high afterload) was robust in predicting diastolic pulmonary pressure gradient (DPG) elevation.Recorded at the 2015 ATS Annual Conference.
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!